

FINAL RESUME ON THE RESEARCH UNIT:  
Hematopoietic stem cells and the development  
of myeloid malignancy

UNDER THE SUPERVISION OF THE  
FOLLOWING INSTITUTIONS AND  
RESEARCH BODIES:

Université Paris-Sud

Institut national de la santé et de la recherche  
médicale - Inserm

---

**EVALUATION CAMPAIGN 2018-2019**  
GROUP E



In the name of Hcéres<sup>1</sup>:

Michel Cosnard, President

In the name of the experts committee<sup>2</sup>:

Jean Soulier, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

<sup>2</sup> The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Tables in this document were filled with data provided by laboratories and supervising bodies in the unit's application and in the Excel files "Données du contrat en cours" and "Données du prochain contrat".

## UNIT PRESENTATION

<b>Unit name:</b>	Hematopoietic stem cells and the development of myeloid malignancies
<b>Unit acronym:</b>	n/a
<b>Requested label:</b>	
<b>Application type:</b>	Restructuration
<b>Current number:</b>	U1170
<b>Head of the unit (2018-2019):</b>	Mr Olivier BERNARD
<b>Project leader (2020-2024):</b>	Ms Françoise PORTEU
<b>Number of teams:</b>	2

## EXPERTS COMMITTEE MEMBERS

<b>Chair:</b>	Mr Jean SOULIER, Hôpital St Louis and University Paris Diderot, Paris
<b>Experts:</b>	Ms Catherine ROBIN, Hubrecht Institute, The Netherlands
	Mr Tim SOMERVILLE, Cancer Research UK Manchester Institute, United Kingdom
	Mr Frédéric MAZURIER, Université de Tours (representative of Inserm CSS)
	Mr Christophe VANBELLE, Inserm de Lyon (supporting personnel)

## HCÉRES REPRESENTATIVE

Ms Urszula HIBNER

## REPRESENTATIVES OF SUPERVISING INSTITUTIONS AND BODIES

Mr Etienne AUGÉ, Université Paris Sud

Mr Laurent DELVA, Inserm

Ms Laurence PARMENTIER, Inserm

## INTRODUCTION

### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

There is a long history of research in normal and pathologic hematopoiesis at Institute Gustave Roussy (IGR, Villejuif), with landmark discoveries over the years (TPO, JAK2-V617F, TET2...). The Inserm unit historically led by W. Vainchenker at the Pavillon de Recherche IGR merged in 2010 with the unit led by E. Solary, coming from Dijon Faculty, and with the group of O. Bernard, coming from Necker, and in 2014 with the group of F. Porteu from Cochin, resulting in the current Inserm U1170 unit led by O. Bernard. This unit, which gathers more than 100 researchers, will split into two units for the next contract. The present project builds a "Hematopoietic stem cells and the development of myeloid malignancies" unit based on two existing teams from U1170.

### MANAGEMENT TEAM

The unit will be headed by F. Porteu.

### HCÉRES NOMENCLATURE

SVE5\_4.

### SCIENTIFIC DOMAIN

Research topics are benign and malignant hematopoietic disorders, megakaryocytes, monocytes, cytokines, constitutive predisposition to hematopoietic disorders, myeloid malignancies including myeloproliferative neoplasia, hematopoietic stem/progenitor cells, aging, DNA damage, and hematopoietic development.

### UNIT WORKFORCE

	Unit workforce	
	Hematopoietic stem cell and the development of myeloid malignancies	
Active staff	Number 30/06/2018	Number 01/01/2020
Full professors and similar positions	3	1
Assistant professors and similar positions	1	1
Full time research directors (Directeurs de recherche) and similar positions	11	4
Full time research associates (Chargés de recherche) and similar positions	9	5
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	2	5
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	6	3

<b>Permanent staff</b>	<b>32</b>	<b>19</b>
Non-permanent professors and associate professors, including emeritus	2	
Non-permanent full time scientists, including emeritus, post-docs	19	
PhD Students	27	
Non-permanent supporting personnel	12	
<b>Non-permanent staff</b>	<b>53</b>	
<b>Total</b>	<b>85</b>	

## GLOBAL ASSESSMENT OF THE UNIT

The teams composing of the future unit "Hematopoietic stem cells and the development of myeloid malignancies" have produced top international level science in the past 5 years, bringing together fundamental and translational research in benign and malignant hematology, in the field of constitutive predisposition to hematopoietic disorders, myeloid malignancies and myeloproliferative neoplasia including chronic myelomonocytic leukemia (CMML), hematopoietic stem/progenitor cells and response to DNA damage. PI and collaborators have published original articles in high-ranking journals such as *Nature Genetics*, *Nature Communications*, *Blood*, *JCO*, *J Clin Invest* and *Leukemia*. All PIs have national visibility, while some have excellent or even exceptional international visibility. Collectively the team members have obtained many national grants (INCa, ANR, ARC, industrial contracts from pharma). Several young researchers have consolidated the unit with permanent scientists positions in existing teams. There is a strong involvement in teaching experimental hematology from several members of the unit. The unit is affiliated to two Doctoral Schools, namely Oncology Paris Sud/Paris Saclay and Hematology-Oncogenesis-Biotherapy Paris Diderot/Paris Descartes/Paris Sud, which have provided many students. The overall scientific project of the unit is excellent and logically relies on the previous structure as a continuation of research program of the previous individual teams.

The evaluation reports of Hceres  
are available online :[www.hceres.com](http://www.hceres.com)

**Evaluation of clusters of higher education and research institutions**

**Evaluation of higher education and research institutions**

**Evaluation of research**

**Evaluation of doctoral schools**

**Evaluation of programmes**

**International evaluation and accreditation**



2 rue Albert Einstein  
75013 Paris, France  
T. 33 (0)1 55 55 60 10

[hceres.com](http://hceres.com)

[@Hceres\\_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)